艾迪注射液对人胃癌HGC-27细胞的抗肿瘤作用机制研究  

Anti-tumor mechanism of Aidi injection on human gastric cancer HGC 27 cells

作　　者：陈溪雯 钱亚云[1] CHEN Xiwen;QIAN Yayun(Yangzhou University Medical College(Translational Medicine Research Institute of Yangzhou University)/the Key Laboratory of Syndrome Differentiation and Treatment of Gastric Cancer of the State Administration of Traditional Chinese Medicine,Yangzhou 225001,Jiangsu,China)

机构地区：[1]扬州大学医学院(扬州大学转化医学研究院)/国家中医药管理局胃癌毒邪论治重点研究室,江苏扬州2250010

出　　处：《癌症进展》2021年第9期887-890,895,共5页Oncology Progress

基　　金：国家自然科学基金(81403232);江苏省自然科学基金项目(BK20171290、BK2012686);江苏省高等学校自然科学研究重大项目(19KJA480003)。

摘　　要：目的探讨艾迪注射液对人胃癌HGC-27细胞增殖和迁移能力的影响及作用机制研究。方法采用0、7.5、15.0、30.0、60.0、120.0 mg/ml艾迪注射液处理人胃癌HGC-27细胞,采用噻唑蓝(MTT)法检测细胞增殖能力。不同浓度艾迪注射液培养人胃癌HGC-27细胞48 h的半数抑制浓度(IC50)为20.17 mg/ml,后续实验将6.0、12.0、24.0 mg/ml艾迪注射液处理的人胃癌HGC-27细胞设置为低浓度组、中浓度组、高浓度组,以野生型HGC-27细胞作为空白对照组,2.0 mg/L顺铂处理的胃癌细胞HGC-27作为阳性对照组,细胞划痕试验检测细胞的迁移能力,蛋白质印迹法(Westernblot)检测各组细胞蛋白激酶B(AKT)、雷帕霉素靶蛋白(MTOR)、真核起始因子4E结合蛋白1(4EBP1)、磷酸化的4EBP1(p-4EBP1)蛋白的相对表达量。结果随艾迪注射液浓度的升高,培养24、48、72 h,人胃癌HGC-27细胞A值均逐渐降低,差异均有统计学意义(P﹤0.05)。培养24 h,低浓度组、中浓度组、高浓度组人胃癌HGC-27细胞未迁移率均高于空白对照组(P﹤0.05),高浓度组人胃癌HGC-27细胞未迁移率高于低浓度和中浓度组(P﹤0.05)。低浓度组和中浓度组人胃癌HGC-27细胞AKT、4EBP1、p-4EBP1蛋白的相对表达量均低于空白对照组(P﹤0.05),且中浓度组人胃癌HGC-27细胞MTOR蛋白相对表达量低于空白对照组(P﹤0.05),高浓度组人胃癌HGC-27细胞AKT、MTOR、4EBP1、p-4EBP1蛋白相对表达量均低于低浓度组和中浓度组,中浓度组人胃癌HGC-27细胞AKT蛋白相对表达量高于低浓度组,差异均有统计学意义(P﹤0.05)。结论艾迪注射液能够抑制人胃癌HGC-27细胞的增殖和迁移能力,且MTOR信号通路可能是其抗胃癌治疗的关键。Objective To investigate the effect of Aidi injection on the proliferation and migration of human gastric cancer HGC-27 cells and its underlying mechanism.Method Human gastric cancer HGC-27 cells were treated with 0,7.5,15.0,30.0,60.0,120.0 mg/ml Aidi injection,and the cell proliferation ability was detected by the methyl thiazolyl tetrazolium(MTT)method.The half inhibit concentration(IC50)of Aidi injection on human gastric cancer HGC-27 cells for48 hours was 20.17 mg/ml.The subsequent experiments used 6.0,12.0,and 24.0 mg/ml of Aidi injection for human gastric cancer HGC-27 cells as low concentration group,medium concentration group,high concentration group,with wildtype HGC-27 cells as a blank control group,and gastric cancer HGC-27 cells treated with 2.0 mg/L cisplatin as a positive control group.The detection of cell migration was based on the cell scratch method.The relative expression of protein kinase B(AKT),mechanistic target of rapamycin kinase(MTOR),eukaryotic translation initiation factor 4 E binding protein 1(4 EBP1),and phospho-4 EBP1(p-4 EBP1)protein were measured by the Western blot in each group.Result With the increase of the concentration of Aidi injection,the A value of human gastric cancer HGC-27 cells gradually decreased after 24,48,and 72 hours of culture,and the differences were statistically significant(P<0.05).After 24 hours of culture,the non-migration rate of human gastric cancer HGC-27 cells in the low concentration group,medium concentration group,and high concentration group was higher than that of the blank control group(P<0.05),and the non-migration rate of human gastric cancer HGC-27 cells in the high concentration group was higher than that in the low concentration and medium concentration group(P<0.05).The relative expression levels of AKT,4 EBP1,and p-4 EBP1 in human gastric cancer HGC-27 cells in the low concentration group and the medium concentration group were lower than those in the blank control group(P<0.05),and the relative expression of MTOR protein in human gastric ca

关 键 词：艾迪注射液 胃癌 雷帕霉素靶蛋白 侵袭 迁移 

分 类 号：R735.2[医药卫生—肿瘤]